Merck Developing Singulair/Loratadine Combination For Asthma
Executive Summary
Combining Singulair and loratadine, the active ingredient in Claritin, for asthma could result in a 3%-4% increase in efficacy, Merck Research Labs President Edward Scolnick told securities analysts Dec. 9 in Whitehouse Station, N.J.
You may also be interested in...
Merck Vioxx Gains 60,000 Scripts Each Week; $92 Mil. In U.S. Sales To Date
Nearly half of new Vioxx (refecoxib) scripts are for newly-diagnosed osteoarthritis patients or patients switching to a prescription medication from an over-the-counter treatment, Merck Investor Relations Director Laura Jordan said during a second quarter earnings teleconference July 23.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011